Vascular Endothelial Growth Factors
"Vascular Endothelial Growth Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.
| Descriptor ID |
D042442
|
| MeSH Number(s) |
D12.644.276.100.800 D12.776.467.100.800 D23.529.100.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factors".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factors".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factors" by people in this website by year, and whether "Vascular Endothelial Growth Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 9 | 9 |
| 2003 | 0 | 3 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factors" by people in Profiles.
-
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022; 7(1):e000957.
-
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
-
Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc. 2010 Oct; 24(10):2581-7.
-
VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Invest. 2005 Nov; 35(11):669-76.
-
RSV causes HIF-1alpha stabilization via NO release in primary bronchial epithelial cells. Inflammation. 2004 Oct; 28(5):245-51.
-
Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol. 2004 Sep; 25(3):549-53.
-
Respiratory syncytial virus causes increased bronchial epithelial permeability. Chest. 2004 Jul; 126(1):186-91.
-
Biomolecular markers and involution of hemangiomas. J Pediatr Surg. 2004 Mar; 39(3):400-4.
-
Topical VEGF enhances healing of thoracic aortic anastomosis for coarctation in a rabbit model. Circulation. 2003 Sep 09; 108 Suppl 1:II150-4.
-
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003 Jun 24; 100(13):7785-90.